
Talha Badar: Moving immunotherapy upfront in B-cell ALL
Moving immunotherapy upfront in B-cell ALL.
Due to increased understanding of disease biology, resistance/toxicity from chemotherapy, field is moving towards early introduction of targeted molecule and immunotherapy.
INO, an anti-CD22 Ab was approved for RR ALL based on INO-VATE study:
- higher CR rate 81% vs 29%; P < .001); MRD 78% vs 28% after SOC P < .001.
Among the patients who received allo-HSCT after INO, 22% had VOD
DOI: 10.1056/NEJMoa1509277
Phase II study of InO plus mini hyper CVD upfront for B-cell ALL; 2 yrs PFS was 59% and OS 66%.
Click here for the article.
Several trials now incorporating InO ealry in Rx of B-cell ALL below.
Blinatumomab (CD3-CD19 bispecific) was approved for RR B-cell ALL based on positive results of PIII:
- higher ORR 44% vs. 25%, P<0.001
- mOS 7.7 vs 4.0 mo.
DOI: 10.1056/NEJMoa1609783
HyperCVAD plus sequential Blina for Ph-ve B-cell ALL.
4 # of HyperCVAD leads to 4 # of Blina leads to 3 cycles of POMP alternating with 1 cycle of Blina for 15 cycles.
- 38 pts: CR 100%,
- MRD -ve 97%, 3-yr OS 81%
Impressive results, including pts with HR disease.
10.1016/S2352-3026(22)00285-X
Blina followed by POMP maintenance in elderly with Ph-ve B cell ALL (SWOG 1318).
29 pts, median age 75 yrs, poor risk 34%.
CR 66%, 3 yrs DFS and OS 37% each
DOI: 10.1200/JCO.21.01766
E1910 trial incorporating Blina with chemotherapy in MRD -ve B-cell ALL.
Primary endpoint was OS and it was met!
Chemotherapy free Rx for elderly B-cell ALL: InO and Blina for older:
Alliance A041703
Phase II trial of induction InO then blina for older adults with newly-diagnosed (ND), Ph-, B-ALL.
- 33 pts, CR after course II 97%, 1 yr EFS 75%, 1 yr OS 84%.
Click here for the article.
Several trials now incorporating Blina early in Rx of B-cell ALL below.
Chemo-free regimen for Ph+ve ALL with upfront immunotherapy.
Excellent responses with 2 yrs OS > 90%.
Click here for the article.
Summary:
It is high time to incorporate immunotherapy upfront in Rx of B-cell ALL:
- Less toxic
- More effective with durable responses
- Effective in high risk pts. “
-
12:46 30/11/23 | BlogJohanna Joyce: the Flashlight method
-
12:31 30/11/23 | InsightJeff Ryckman: Omitting RT in bulky early-stage cHL
-
07:45 30/11/23 | BlogAaron Goodman: Hemoglobin Dissociation Curve! Good stuff
-
12:31 30/11Jeff Ryckman: Omitting RT in bulky early-stage cHL
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows